Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
November 25 2020 - 1:28PM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that Dr. Jennifer Buell,
President and COO of Agenus, will participate in a fireside chat
hosted by Umer Raffat at the Evercore ISI 3rd Annual HealthCONx
Conference on Thursday, December 3, 2020 from 10:55 AM – 11:15 AM
EST.
Dr. Buell will provide an update on clinical programs, including
AGEN1181, and corporate progress.
Registration for the webinar can be done in advance at
https://wsw.com/webcast/evercore11/register.aspx?conf=evercore11&page=agen&url=https://wsw.com/webcast/evercore11/agen/2321775.
A replay will be available after the call on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Contact:Agenus
Inc. Caroline Bafundo
212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024